Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211

Background. Vicriviroc, an investigational CCR5 inhibitor, demonstrated short-term antiretroviral activity in a phase 1 study. Methods. The present study was a double-blind, randomized phase 2 study of vicriviroc in treatment-experienced, human immunodeficiency virus (HIV)–infected subjects experien...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of infectious diseases 2007-07, Vol.196 (2), p.304-312
Hauptverfasser:	Gulick, Roy M., Su, Zhaohui, Flexner, Charles, Hughes, Michael D., Skolnik, Paul R., Wilkin, Timothy J., Gross, Robert, Krambrink, Amy, Coakley, Eoin, Greaves, Wayne L., Zolopa, Andrew, Reichman, Richard, Godfrey, Catherine, Hirsch, Martin, Kuritzkes, Daniel R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult AIDS Anti-Retroviral Agents - adverse effects Anti-Retroviral Agents - therapeutic use Antiretrovirals CCR5 Receptor Antagonists CD4 Lymphocyte Count Clinical trials Dosage Double-Blind Method Drug Therapy, Combination Female HIV 1 HIV Infections - drug therapy HIV Infections - prevention & control HIV-1 - classification HIV-1 - drug effects HIV/AIDS Human immunodeficiency virus 1 Human immunodeficiency virus 2 Humans Male Middle Aged Piperazines - adverse effects Piperazines - therapeutic use Placebos Pyrimidines - adverse effects Pyrimidines - therapeutic use Receptors Ritonavir - therapeutic use RNA RNA, Viral - analysis RNA, Viral - drug effects Viral Load Virology Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!